Who's Afraid Of Patent Losses? Merck, Schering, BMS Defenses Play Well
Executive Summary
Merck has regenerating brands; Schering-Plough has desloratadine; Bristol-Myers Squibb has an 11th-hour patent and a combo replacement for a major single-ingredient expiration; and they all have recession-haven reputations.
You may also be interested in...
Waxman/Hatch Reform Should Clarify Rules, Not Change System - Merck
Reforms to the Waxman/Hatch patent extension program should focus on "clarification" of patent life, rather than "fundamental changes" to the generic drug approval and extension process, Merck Senior Director-Government Relations Ian Spatz told the National Institute for Health Care Management Sept. 25 in Washington, D.C.
Medco "YOURxPLAN" Preferred List Includes 13 Schering Drugs, Cenestin
The Merck-Medco/Reader's Digest "YOURxPLAN" prescription discount service includes 13 Schering-Plough drugs on its list of "select" products that generate cash refunds to enrollees.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011